Showing 1 - 20 results of 794 for search '"he-4"', query time: 1.23s Refine Results
  1. 1
  2. 2
    Academic Journal

    Source: IEEE Transactions on Nuclear Science IEEE Trans. Nucl. Sci. Nuclear Science, IEEE Transactions on. 69(6):1331-1335 Jun, 2022

    Linked Full Text
  3. 3
    Academic Journal

    Source: The Lancet Oncology. 25:1371-1386

    Linked Full Text
  4. 4
  5. 5
    Academic Journal

    Contributors: HEP, INSPIRE, Laboratoire de Physique des 2 Infinis Irène Joliot-Curie (IJCLab), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Laboratoire Kastler Brossel (LKB Collège de France ), Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), École normale supérieure - Paris (ENS-PSL), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Collège de France (CdF (institution))-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)

    Source: Physics, Vol 6, Iss 1, Pp 206-215 (2024)
    Physics, 6 (1)
    Physics

    File Description: application/application/pdf

  6. 6
    Academic Journal

    Authors: Moskalev, O.Aff1, Yukhimchuk, A.Aff1, IDS002713492470173X_cor1, Maksimkin, I.Aff1, Loginov, M.Aff1, Baluev, V.Aff1, Musyaev, R.Aff1, Vyalkov, M.Aff1, Aff2, Aff3, Verkhovtsev, M.Aff1, Aff2, Aff3, Studenikin, A.Aff3, Kouzakov, K.Aff3, Tkachev, I.Aff4, Ivashkin, A.Aff4, Trofimov, V.Aff5, Eremin, V.Aff6

    Source: Moscow University Physics Bulletin. 79(Suppl 1):252-255

    Linked Full Text
  7. 7
    Academic Journal

    Source: Moscow University Physics Bulletin. 79(Suppl 1):243-251

    Linked Full Text
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
    Academic Journal

    Authors: Jebali, R., Author, Scherzinger, J., Author, Annand, J. R. M., Author, Chandra, R., Author, Davatz, G., Author, Fissum, K. G., Author, Friederich, H., Author, Gendotti, U., Author, Hall-Wilton, Richard, Author, Hakansson, E., Author, Kanaki, K., Author, Lundin, M., Author, Murer, D., Author, Nilsson, B., Author, Rosborg, A., Author, Svensson, H., Author

    Contributors: Jebali, R., Author, Scherzinger, J., Author, Annand, J. R. M., Author, Chandra, R., Author, Davatz, G., Author, Fissum, K. G., Author, Friederich, H., Author, Gendotti, U., Author, Hall-Wilton, Richard, Author, Hakansson, E., Author, Kanaki, K., Author, Lundin, M., Author, Murer, D., Author, Nilsson, B., Author, Rosborg, A., Author, Svensson, H., Author

    Source: Nuclear Instruments and Methods in Physics Research Section A. 794:102-108

    File Description: electronic

  14. 14
  15. 15
    Academic Journal

    Source: Siberian journal of oncology; Том 24, № 5 (2025); 53-63 ; Сибирский онкологический журнал; Том 24, № 5 (2025); 53-63 ; 2312-3168 ; 1814-4861

    File Description: application/pdf

    Relation: https://www.siboncoj.ru/jour/article/view/3857/1397; https://www.siboncoj.ru/jour/article/downloadSuppFile/3857/8865; https://www.siboncoj.ru/jour/article/downloadSuppFile/3857/8866; Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2024. 276 с. ISBN: 978-585502-298-8.; Состояние онкологической помощи населению России в 2023 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2024. 262 с. ISBN: 978-5-85502-297-1.; Злокачественное новообразование бронхов и легкого: клинические рекомендации (одобрено Минздравом РФ). 2021. [cited 17.09.2025]. URL: https://oncology-association.ru/wp-content/uploads/2021/02/rak-legkogo-2021.pdf.; Muller M., Hoogendoorn R., Moritz R.J.G., van der Noort V., Lanfermeijer M., Korse C.M., van den Broek D., Ten Hoeve J.J., Baas P., van Rossum H.H., van den Heuvel M.M. Validation of a clinical bloodbased decision aid to guide immunotherapy treatment in patients with non-small cell lung cancer. Tumour Biol. 2021; 43(1): 115–27. doi:10.3233/TUB-211504.; Chen Z., Liu X., Shang X., Qi K., Zhang S. The diagnostic value of the combination of carcinoembryonic antigen, squamous cell carcinoma-related antigen, CYFRA 21-1, neuron-specific enolase, tissue polypeptide antigen, and progastrin-releasing peptide in small cell lung cancer discrimination. Int J Biol Markers. 2021; 36(4): 36–44. doi:10.1177/17246008211049446.; Braicu E.I., Krause C.L., Torsten U., Mecke H., Richter R., Hellmeyer L., Lanowska M., Müller B., Koch E., Boenneß-Zaloum J., Ames K., Chekerov R., Hasenbein K., Zimmermann M., Mangler M., Chen F., Tauber R., Sehouli J. HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients. BMC Cancer. 2022; 22(1): 831. doi:10.1186/s12885-022-09887-5.; Du Q., Yan C., Wu S.G., Zhang W., Huang C., Yao Y., Wang L., Zhang Q., Liu Q., Guan J., Hou Y., Li Z., Soh A., Beshiri A., Wang Q., Li X., Zheng Y., Wang H. Development and validation of a novel diagnostic nomogram model based on tumor markers for assessing cancer risk of pulmonary lesions: A multicenter study in Chinese population. Cancer Lett. 2018; 420: 236–41. doi:10.1016/j.canlet.2018.01.079.; Wang Y., Wang Z., Ding Y., Sun F., Ding X. The application value of serum HE4 in the diagnosis of lung cancer. Asian Pac J Cancer Prev. 2019; 20(8): 2405–407. doi:10.31557/APJCP.2019.20.8.2405.; Guo L., Song B., Xiao J., Lin H., Chen J., Su X. The prognostic value of biomarkers on detecting non-small cell lung cancer in a Chinese elderly population. Int J Gen Med. 2021; 14: 5279–86. doi:10.2147/IJGM.S331311.; Li J., Li Y., Huo L., Sun R., Liu X., Gu Q., Li A., Han S., Liu H., Li Y., Zhang Y. Detection of serum HE4 levels contributes to the diagnosis of lung cancer. Oncol Lett. 2023; 25(6): 255. doi:10.3892/ol.2023.13841.; Wu L., Chen X., Peng T., Tang E., Bai W., Chen L. Human epididymal protein 4 and its combined detection show good diagnostic value in lung cancer: A retrospective study. Int J Biol Markers. 2024; 39(2): 141–48. doi:10.1177/03936155241244802.; Zhang T., Chu L., Tan W., Ye C., Dong H. Human epididymis protein 4, a novel potential biomarker for diagnostic and prognosis monitoring of lung cancer. Clin Respir J. 2024; 18(5): e13774. doi:10.1111/crj.13774.; Dai C., Zheng Y., Li, Y., Tian T., Wang M., Xu P., Deng Y., Hao Q., Wu Y., Zhai Z., Dai Z., Lyu J. Prognostic values of HE4 expression in patients with cancer: a meta-analysis. Cancer Manag Res. 2018; 10: 4491–500. doi:10.2147/CMAR.S178345.; Zare M.E., Nasir Kansestani A., Wu X., Zhou L., Lu J., Huang J., Wang Y., Ma Y., Gao Y., Zhang J. Serum human epididymis Protein-4 outperforms conventional biomarkers in the early detection of nonsmall cell lung cancer. iScience. 2024; 27(11): 111211. doi:10.1016/j.isci.2024.111211.; la Salvia A., Fanciulli G. Progastrin-releasing peptide as a diagnostic biomarker of pulmonary and non-pulmonary neuroendocrine neoplasms. Endocr Res. 2024; 49(4): 243–50. doi:10.1080/07435800.2024.2365895.; Bolstad N., Øijordsbakken M., Nustad K., Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2012; 33(1): 141–48. doi:10.1007/s13277-011-0256-4.; Hertlein L., Stieber P., Kirschenhofer A., Krocker K., Nagel D., Lenhard M., Burges A. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med. 2012; 50(12): 2181–88. doi:10.1515/cclm-2012-0097.; He Y.P., Li L.X., Tang J.X., Yi L., Zhao Y., Zhang H.W., Wu Z.J., Lei H.K., Yu H.Q., Nian W.Q., Gan L. HE4 as a biomarker for diagnosis of lung cancer: A meta-analysis. Medicine (Baltimore). 2019; 98(39): e17198. doi:10.1097/MD.0000000000017198.; Choi S.I., Jang M.A., Jeon B.R., Shin H.B., Lee Y.K., Lee Y.W. Clinical usefulness of human epididymis protein 4 in lung cancer. Ann Lab Med. 2017; 37(6): 526–30. doi:10.3343/alm.2017.37.6.526.; Kumbasar U., Dikimen Z.G., Yilmaz Y., Ancin B., Dikimen E., Dogan R. Serum human epididymis protein 4 (HE4) as a diagnostic and follow-up biomarker in patients with non-small cell lung cancer. Int J Hematol Oncol. 2017; 27(3): 137–42. doi:10.4999/uhod.171830.; Li M., Zhang Y., Jiang L., Li Y., Li G., Zhou J., Yang C., Li X., Qu W., Chen Y., Chen Q., Wang S., Xing J., Huang H. New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarkes. Neoplasma. 2022; 69(3): 729–40. doi:10.4149/neo_2022_220207N144.; Huang W., Wu S., Lin Z., Chen P., Wu G. Evaluation of HE4 in the diagnosis and follow up of non-small cell lung cancers. Clin Lab. 2017; 63(3): 461–67. doi:10.7754/Clin.Lab.2016.160818.; Li M., Wang F., Wang X., Zhang C. Diagnostic value of human epididymis protein 4 in malignant pleural effusion in lung cancer. Cancer Biomark. 2019; 26(4): 523–28. doi:10.3233/CBM-190840.; Mo D., He F. Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer. Clin Lab. 2018; 64(9): 1421–28. doi:10.7754/Clin.Lab.2018.180222.; Lamy P.J., Plassot C., Pujol J.L. Serum HE4: An independent prognostic factor in non-small cell lung cancer. PloS One. 2015; 10(6): e0128836. doi:10.1371/journal.pone.0128836.; Liu W., Yang J., Chi P.D., Zheng X., Dai S.Q., Chen H., Xu B.L., Liu W.L. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis. Int J Tuberc Lung Dis. 2013; 17(10): 1346–53. doi:10.5588/ijtld.13.0058.; Muley T., He Y., Rolny V., Wehnl B., Escherich A., Warth A., Stolp C., Schneider M.A., Meister M., Herth F.J., Dayyani F. Potential for the bloodbased biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung. Lung Cancer. 2019; 130: 194–200. doi:10.1016/j.lungcan.2019.02.017.; de Kock R., Borne B.V.D., Soud M.Y., Belderbos H., Stege G., de Saegher M., van Dongen-Schrover C., Genet S., Brunsveld L., Scharnhorst V., Deiman B. Circulating biomarkers for monitoring therapy response and detection of disease progression in lung cancer patients. Cancer Treat Res Commun. 2021; 28: 100410. doi:10.1016/j.ctarc.2021.100410.; Zhong H., Qian Y., Fang S., Yang L., Li L., Gu W. HE4 expression in lung cancer, a meta-analysis. Clin Chim Acta. 2017; 470: 109–14. doi:10.1016/j.cca.2017.05.007.; https://www.siboncoj.ru/jour/article/view/3857

  16. 16
  17. 17
  18. 18
  19. 19
  20. 20